Eisai Newsroom http://eisai.mediaroom.com/ Eisai Newsroom Michael Amoroso appointed Senior Vice President, Americas Commercial, Oncology Business Group at Eisai Inc. http://eisai.mediaroom.com/2017-09-25-Michael-Amoroso-appointed-Senior-Vice-President-Americas-Commercial-Oncology-Business-Group-at-Eisai-Inc Mon, 25 Sep 2017 08:00:00 -0400 http://eisai.mediaroom.com/2017-09-25-Michael-Amoroso-appointed-Senior-Vice-President-Americas-Commercial-Oncology-Business-Group-at-Eisai-Inc Combination of Lenvatinib and Pembrolizumab Results in Notable Response Rates for Patients with Advanced Renal Cell Carcinoma Based on Interim Analysis of Ongoing Phase 1b/2 Trial http://eisai.mediaroom.com/2017-09-10-Combination-of-Lenvatinib-and-Pembrolizumab-Results-in-Notable-Response-Rates-for-Patients-with-Advanced-Renal-Cell-Carcinoma-Based-on-Interim-Analysis-of-Ongoing-Phase-1b-2-Trial - Updated results of advanced RCC cohort from Study 111 support continued investigation of first-line use of the combination in ongoing Phase 3 CLEAR study Sun, 10 Sep 2017 08:30:00 -0400 http://eisai.mediaroom.com/2017-09-10-Combination-of-Lenvatinib-and-Pembrolizumab-Results-in-Notable-Response-Rates-for-Patients-with-Advanced-Renal-Cell-Carcinoma-Based-on-Interim-Analysis-of-Ongoing-Phase-1b-2-Trial Lenvatinib Delays Deterioration in Certain Domains of Quality of Life in Patients with Unresectable Hepatocellular Carcinoma as Compared to Sorafenib in Phase 3 REFLECT Study http://eisai.mediaroom.com/2017-09-10-Lenvatinib-Delays-Deterioration-in-Certain-Domains-of-Quality-of-Life-in-Patients-with-Unresectable-Hepatocellular-Carcinoma-as-Compared-to-Sorafenib-in-Phase-3-REFLECT-Study - Quality of life findings follow presentation of positive results at ASCO 2017 in which lenvatinib was the first systemic therapy to demonstrate non-inferiority to sorafenib in overall survival in first-line treatment of patients with unresectable HCC Sun, 10 Sep 2017 06:15:00 -0400 http://eisai.mediaroom.com/2017-09-10-Lenvatinib-Delays-Deterioration-in-Certain-Domains-of-Quality-of-Life-in-Patients-with-Unresectable-Hepatocellular-Carcinoma-as-Compared-to-Sorafenib-in-Phase-3-REFLECT-Study Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress http://eisai.mediaroom.com/2017-08-31-Eisai-to-Present-New-Clinical-Data-in-Variety-of-Advanced-Cancers-at-the-ESMO-2017-Congress - New data in metastatic renal cell carcinoma from Study 111 evaluating lenvatinib in combination with pembrolizumab to be presented in a proffered paper session on Saturday, Sept. 9 at 10:15 a.m. CEST Thu, 31 Aug 2017 16:03:00 -0400 http://eisai.mediaroom.com/2017-08-31-Eisai-to-Present-New-Clinical-Data-in-Variety-of-Advanced-Cancers-at-the-ESMO-2017-Congress Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial http://eisai.mediaroom.com/2017-08-28-Lenvatinib-Significantly-Improved-Overall-Survival-in-Older-Patients-with-Locally-Recurrent-or-Metastatic-Progressive-Radioactive-Iodine-Refractory-Differentiated-Thyroid-Cancer-According-to-Results-of-Subanalysis-of-Phase-3-SELECT-Trial First kinase inhibitor to show improvement in overall survival in any patient group with RAI-R DTC Mon, 28 Aug 2017 07:55:00 -0400 http://eisai.mediaroom.com/2017-08-28-Lenvatinib-Significantly-Improved-Overall-Survival-in-Older-Patients-with-Locally-Recurrent-or-Metastatic-Progressive-Radioactive-Iodine-Refractory-Differentiated-Thyroid-Cancer-According-to-Results-of-Subanalysis-of-Phase-3-SELECT-Trial